Cardiac Myosin Heavy Chain mRNA Gene Expression on Human Cardiovascular Diseases.

Changes in the relative amounts of three cardiac myosin heavy chain (MHC) isozymes V1 : alpha alpha homodimer, V2 : alpha beta heterodimer, and V3 : beta beta homodimer are believed to be responsible, at least in part, for the altered cardiac performance. We have been shown that the distribution of cardiac MHC mRNA expression and isozymes is modified in developmental change, hemodynamic overload, hormonal stimuli and with some drugs. Also, previous studies have demonstrated that the MHC isozyme transition during developmental change, hemodynamic overload and hormonal stimuli is mainly regulateretranslational mechanisms. Based on these results, the aim of this study is to define the methodology of human cardiac MHC gene expression and isozyme distribution using S1 nucrease mapping analysis and pyrophosphate acrylamide gel electrophoresis, respectively, in order to clarify the etiology of disease and early diagnosis. S1 nucrease mapping analysis has been performed using human beta cardiac MHC oligonucleotide as a probe. And also, we succeeded to separate human cardiac MHC isozyme using different composition of pyrophosphate acrylamide gel on very small amount of operative sample (5mg). We think that S1 nucrease mapping analysis and pyrophosphate acrylamide gel electrophoresis are very powerful methods to clarify the etiology of disease and early diagnosis.